Swiss Rockets signed a definitive agreement to acquire Complete Genomics from Chinese parent MGI, moving the U.S. sequencing company out of Chinese ownership and preserving its U.S. base of operations. The transaction transfers R&D, manufacturing and commercial operations to Swiss Rockets and follows an earlier licensing deal for CoolMPS and StandardMPS technologies. Complete Genomics’ management will continue day‑to‑day operations and the company said customer contracts and data handling practices will remain unchanged. Swiss Rockets signaled continuity for product strategy while expanding licensing rights in the Americas and Europe. The deal responds to regulatory and geopolitical pressures on Chinese sequencing vendors and could reshape competitive dynamics in the sequencing tool market if approved by shareholders and regulators.